Literature DB >> 24563375

Systematic reviews to ascertain the safety of diabetes medications.

Michael R Gionfriddo1, Oscar L Morey-Vargas, Juan P Brito, Aaron L Leppin, M Hassan Murad, Victor M Montori.   

Abstract

Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control. With this expansion has come a flurry of concerns about the safety of these antihyperglycemic agents, concerns that affect judgments about the risk/benefit balance of therapy. Some of these safety signals have been identified through the synthesis of existing research evidence. Thus, it has become important for clinicians and clinical policymakers to understand the strengths and limitations of systematic reviews and meta-analyses in determining the safety of diabetes medications. In this paper, we highlight key safety concerns with diabetes medications and discuss the role evidence synthesis plays in each, with special attention to its strengths and limitations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563375      PMCID: PMC4002287          DOI: 10.1007/s11892-014-0478-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  35 in total

1.  Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2013-06-07

2.  Synthesizing evidence: shifting the focus from individual studies to the body of evidence.

Authors:  M Hassan Murad; Victor M Montori
Journal:  JAMA       Date:  2013-06-05       Impact factor: 56.272

3.  Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.

Authors:  Sanjeev N Mehta; Allison B Goldfine; Martin J Abrahamson; Richard DiVincenzo; Lori M B Laffel
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

4.  Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.

Authors:  M Monami; I Dicembrini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-07-28       Impact factor: 6.577

Review 5.  Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  Arch Intern Med       Date:  2010-07-26

6.  Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Authors:  Sonal Singh; Hsien-Yen Chang; Thomas M Richards; Jonathan P Weiner; Jeanne M Clark; Jodi B Segal
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

7.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 8.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

9.  Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Authors:  James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

10.  How can we support the use of systematic reviews in policymaking?

Authors:  John N Lavis
Journal:  PLoS Med       Date:  2009-11-17       Impact factor: 11.069

View more
  2 in total

1.  Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels.

Authors:  Jean-Daniel Lalau; Farshad Kajbaf
Journal:  Int J Endocrinol       Date:  2014-12-17       Impact factor: 3.257

2.  Nightmare and Abnormal Dreams: Rare Side Effects of Metformin?

Authors:  Theo Audi Yanto; Ian Huang; Felicia Nathania Kosasih; Nata Pratama Hardjo Lugito
Journal:  Case Rep Endocrinol       Date:  2018-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.